

News
Auron Therapeutics announces $48 million Series A financing to drive novel oncology pipeline leveraging a machine learning, multi-omics-based platform
Auron expands its leadership team with the appointments of David Millan, Ph.D., as Chief Scientific Officer, Thomas Graeber, Ph.D., as Chief Data Officer, Andrea Armstrong as Chief People Officer and Briggs Morrison, M.D., as Independent Chairman of the Board. Newton, Mass., July 20, 2022 — Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing therapies…
Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers
Wellesley, Mass., Jan. 27, 2021 – Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing differentiation therapies for treating cancer, today announced the completion of its $12.75 million seed financing round. Proceeds will be used to discover and develop novel therapeutics directed toward differentiation therapy, which reactivates endogenous cellular programs to elicit tumor cell maturation…